{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:46:01Z","timestamp":1776167161814,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008321","name":"Pennsylvania State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eat Weight Disord"],"DOI":"10.1007\/s40519-026-01833-9","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:04:37Z","timestamp":1772780677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eating disorder psychopathology relates to weight loss medication and supplement use 6\u00a0months later in women"],"prefix":"10.1007","volume":"31","author":[{"given":"Diane L.","family":"Rosenbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"4","key":"1833_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s11920-012-0282-y","volume":"14","author":"FR Smink","year":"2012","unstructured":"Smink FR, Van Hoeken D, Hoek HW (2012) Epidemiology of eating disorders: incidence, prevalence and mortality rates. Curr Psychiatry Rep 14(4):406\u2013414. https:\/\/doi.org\/10.1007\/s11920-012-0282-y","journal-title":"Curr Psychiatry Rep"},{"issue":"5","key":"1833_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/s0005-7967(02)00088-8","volume":"41","author":"CG Fairburn","year":"2003","unstructured":"Fairburn CG, Cooper Z, Shafran R (2003) Cognitive behaviour therapy for eating disorders: a \u201ctransdiagnostic\u201d theory and treatment. Behav Res Ther 41(5):509\u2013528. https:\/\/doi.org\/10.1016\/s0005-7967(02)00088-8","journal-title":"Behav Res Ther"},{"issue":"4","key":"1833_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.7326\/0003-4819-134-4-200102200-00011","volume":"134","author":"LK Khan","year":"2001","unstructured":"Khan LK, Serdula MK, Bowman BA, Williamson DF (2001) Use of prescription weight loss pills among US adults in 1996\u20131998. Ann Intern Med 134(4):282\u2013286. https:\/\/doi.org\/10.7326\/0003-4819-134-4-200102200-00011","journal-title":"Ann Intern Med"},{"issue":"1","key":"1833_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/asj\/sjad211","volume":"44","author":"SH Han","year":"2024","unstructured":"Han SH, Safeek R, Ockerman K, Trieu N, Mars P, Klenke A et al (2024) Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a google trends analysis. Aesthet Surg J 44(1):60\u201367. https:\/\/doi.org\/10.1093\/asj\/sjad211","journal-title":"Aesthet Surg J"},{"issue":"1","key":"1833_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12020-024-03857-6","volume":"86","author":"B Deng","year":"2024","unstructured":"Deng B, Ruan T, Lu W, Ying J, Li S, Zhou R et al (2024) Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials. Endocrine 86(1):15\u201327. https:\/\/doi.org\/10.1007\/s12020-024-03857-6","journal-title":"Endocrine"},{"issue":"2","key":"1833_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","volume":"48","author":"HJ Wong","year":"2025","unstructured":"Wong HJ, Sim B, Teo YH, Teo YN, Chan MY, Yeo LL et al (2025) Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care 48(2):292\u2013300. https:\/\/doi.org\/10.2337\/dc24-1678","journal-title":"Diabetes Care"},{"issue":"6706","key":"1833_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1126\/science.adn4128","volume":"385","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ (2024) The benefits of GLP-1 drugs beyond obesity. Science 385(6706):258\u2013260. https:\/\/doi.org\/10.1126\/science.adn4128","journal-title":"Science"},{"issue":"2","key":"1833_CR8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/eat.24109","volume":"57","author":"S Bartel","year":"2024","unstructured":"Bartel S, McElroy SL, Levangie D, Keshen A (2024) Use of glucagon\u2010like peptide\u20101 receptor agonists in eating disorder populations. Int J Eat Disord 57(2):286\u2013293. https:\/\/doi.org\/10.1002\/eat.24109","journal-title":"Int J Eat Disord"},{"issue":"1","key":"1833_CR9","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/joe-13-0414","volume":"221","author":"L van Bloemendaal","year":"2014","unstructured":"van Bloemendaal L, ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M (2014) Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 221(1):T1\u2013T16. https:\/\/doi.org\/10.1530\/joe-13-0414","journal-title":"J Endocrinol"},{"key":"1833_CR10","doi-asserted-by":"publisher","first-page":"101890","DOI":"10.1016\/j.bodyim.2025.101890","volume":"53","author":"CH Markey","year":"2025","unstructured":"Markey CH, August KJ, Malik D, Richeson A (2025) Body image and interest in GLP-1 weight loss medications. Body Image 53:101890. https:\/\/doi.org\/10.1016\/j.bodyim.2025.101890","journal-title":"Body Image"},{"key":"1833_CR11","doi-asserted-by":"publisher","first-page":"102013","DOI":"10.1016\/j.eatbeh.2025.102013","volume":"58","author":"KT Ganson","year":"2025","unstructured":"Ganson KT, Testa A, Lavender JM, Nagata JM (2025) Prescription weight loss medication use and eating disorder psychopathology among adolescent boys and young men from Canada and the United States. Eat Behav 58:102013. https:\/\/doi.org\/10.1016\/j.eatbeh.2025.102013","journal-title":"Eat Behav"},{"issue":"5","key":"1833_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.biopsych.2018.03.014","volume":"84","author":"T Udo","year":"2018","unstructured":"Udo T, Grilo CM (2018) Prevalence and correlates of DSM-5\u2013defined eating disorders in a nationally representative sample of U.S. adults. Biol Psychiatry 84(5):345\u2013354. https:\/\/doi.org\/10.1016\/j.biopsych.2018.03.014","journal-title":"Biol Psychiatry"},{"issue":"4","key":"1833_CR13","doi-asserted-by":"publisher","first-page":"100353","DOI":"10.1016\/j.peh.2025.100353","volume":"13","author":"D Martin","year":"2025","unstructured":"Martin D, Hawkins RM, Gee TI, Turnock L, Lazuras L (2025) Use of glucagon-like peptide 1 (GLP-1) agonists among exercisers and recreational athletes and associated mental health symptoms. Perform Enhanc Health 13(4):100353. https:\/\/doi.org\/10.1016\/j.peh.2025.100353","journal-title":"Perform Enhanc Health"},{"issue":"2","key":"1833_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JCP.0000000000001820","volume":"44","author":"AI Guerdjikova","year":"2024","unstructured":"Guerdjikova AI, Ward A, Ontiveros M, McElroy SL (2024) Semaglutide misuse in atypical anorexia nervosa\u2014a case report. J Clin Psychopharmacol 44(2):179\u2013180. https:\/\/doi.org\/10.1097\/JCP.0000000000001820","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1833_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/JCP.0000000000001975","volume":"45","author":"AI Guerdjikova","year":"2025","unstructured":"Guerdjikova AI, Dlugosz H, Wolterman R, McElroy SL (2025) Relapse in anorexia nervosa associated with tirzepatide: a case report. J Clin Psychopharmacol 45(3):287\u2013288. https:\/\/doi.org\/10.1097\/JCP.0000000000001975","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1833_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jada.2006.12.009","volume":"107","author":"HM Blanck","year":"2007","unstructured":"Blanck HM, Serdula MK, Gillespie C, Galuska DA, Sharpe PA, Conway JM et al (2007) Use of nonprescription dietary supplements for weight loss is common among Americans. J Am Diet Assoc 107(3):441\u2013447. https:\/\/doi.org\/10.1016\/j.jada.2006.12.009","journal-title":"J Am Diet Assoc"},{"issue":"4","key":"1833_CR17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/oby.2007.136","volume":"16","author":"JL Pillitteri","year":"2008","unstructured":"Pillitteri JL, Shiffman S, Rohay JM, Harkins AM, Burton SL, Wadden TA (2008) Use of dietary supplements for weight loss in the United States: results of a national survey. Obesity 16(4):790\u2013796. https:\/\/doi.org\/10.1038\/oby.2007.136","journal-title":"Obesity"},{"issue":"2","key":"1833_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/1745790413480521","volume":"13","author":"MD Kaplan","year":"2013","unstructured":"Kaplan MD, Kasnako\u00fc\u011flu BT, Yigitbasi T, Kaplan YC (2013) Evaluation of satisfaction with over-the-counter weight loss supplements. J Med Market 13(2):68\u201373. https:\/\/doi.org\/10.1177\/1745790413480521","journal-title":"J Med Market"},{"issue":"2","key":"1833_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/1098-108X(198803)7:2<211::AID-EAT2260070208>3.0.CO;2-C","volume":"7","author":"JE Mitchell","year":"1988","unstructured":"Mitchell JE, Pomeroy C, Huber M (1988) A clinician\u2019s guide to the eating disorders medicine cabinet. Int J Eat Disord 7(2):211\u2013223. https:\/\/doi.org\/10.1002\/1098-108X(198803)7:2%3c211::AID-EAT2260070208%3e3.0.CO;2-C","journal-title":"Int J Eat Disord"},{"issue":"5","key":"1833_CR20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.hrthm.2009.02.021","volume":"6","author":"A Nazeri","year":"2009","unstructured":"Nazeri A, Massumi A, Wilson JM, Frank CM, Bensler M, Cheng J et al (2009) Arrhythmogenicity of weight-loss supplements marketed on the Internet. Heart Rhythm 6(5):658\u2013662. https:\/\/doi.org\/10.1016\/j.hrthm.2009.02.021","journal-title":"Heart Rhythm"},{"issue":"3","key":"1833_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/jat\/30.3.219","volume":"30","author":"EJ Miranda","year":"2006","unstructured":"Miranda EJ, McIntyre IM, Parker DR, Gary RD, Logan BK (2006) Two deaths attributed to the use of 2, 4-dinitrophenol. J Anal Toxicol 30(3):219\u2013222. https:\/\/doi.org\/10.1093\/jat\/30.3.219","journal-title":"J Anal Toxicol"},{"issue":"4","key":"1833_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1081\/clt-58946","volume":"43","author":"AL Hsiao","year":"2005","unstructured":"Hsiao AL, Santucci KA, Seo-Mayer P, Mariappan MR, Hodsdon ME, Banasiak KJ et al (2005) Pediatric fatality following ingestion of dinitrophenol: postmortem identification of a \u201cdietary supplement.\u201d Clin Toxicol 43(4):281\u2013285. https:\/\/doi.org\/10.1081\/clt-58946","journal-title":"Clin Toxicol"},{"issue":"8","key":"1833_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/eat.20233","volume":"39","author":"KJ Steffen","year":"2006","unstructured":"Steffen KJ, Roerig JL, Mitchell JE, Crosby RD (2006) A survey of herbal and alternative medication use among participants with eating disorder symptoms. Int J Eat Disord 39(8):741\u2013746. https:\/\/doi.org\/10.1002\/eat.20233","journal-title":"Int J Eat Disord"},{"issue":"7","key":"1833_CR24","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/eat.23531","volume":"54","author":"VM Hazzard","year":"2021","unstructured":"Hazzard VM, Simone M, Austin SB, Larson N, Neumark-Sztainer D (2021) Diet pill and laxative use for weight control predicts first-time receipt of an eating disorder diagnosis within the next 5 years among female adolescents and young adults. Int J Eat Disord 54(7):1289\u20131294. https:\/\/doi.org\/10.1002\/eat.23531","journal-title":"Int J Eat Disord"},{"issue":"1","key":"1833_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2105\/AJPH.2019.305390","volume":"110","author":"JA Levinson","year":"2020","unstructured":"Levinson JA, Sarda V, Sonneville K, Calzo JP, Ambwani S, Austin SB (2020) Diet pill and laxative use for weight control and subsequent incident eating disorder in US young women: 2001\u20132016. Am J Public Health 110(1):109\u2013111. https:\/\/doi.org\/10.2105\/AJPH.2019.305390","journal-title":"Am J Public Health"},{"issue":"11","key":"1833_CR26","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.healthpol.2021.09.007","volume":"125","author":"C Moureaud","year":"2021","unstructured":"Moureaud C, Hertig J, Dong Y, Muraro IS, Alhabash S (2021) Purchase of prescription medicines via social media: a survey-based study of prevalence, risk perceptions, and motivations. Health Policy 125(11):1421\u20131429. https:\/\/doi.org\/10.1016\/j.healthpol.2021.09.007","journal-title":"Health Policy"},{"key":"1833_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1239507","author":"H Almomani","year":"2023","unstructured":"Almomani H, Raza A, Patel N, Donyai P (2023) Reasons that lead people to buy prescription medicines on the internet: a systematic review. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1239507","journal-title":"Front Pharmacol"},{"key":"1833_CR28","doi-asserted-by":"publisher","first-page":"e65440","DOI":"10.2196\/65440","volume":"26","author":"AR Ashraf","year":"2024","unstructured":"Ashraf AR, Mackey TK, Vida RG, Kulcs\u00e1r G, Schmidt J, Bal\u00e1zs O et al (2024) Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: market surveillance, content analysis, and product purchase evaluation study. J Med Internet Res 26:e65440. https:\/\/doi.org\/10.2196\/65440","journal-title":"J Med Internet Res"},{"key":"1833_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4324\/9781315148328-22","volume-title":"Human enhancement drugs","author":"J Germain","year":"2019","unstructured":"Germain J, McLean C, Leavey C (2019) One size does not fit all: tackling the issue of weight-loss drug use. In: Ven K, Mulrooney K, McVeigh J (eds) Human enhancement drugs. Routledge, London, pp 313\u201323"},{"issue":"4","key":"1833_CR30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/mop.0000000000001356","volume":"36","author":"K Gordon","year":"2024","unstructured":"Gordon K, Matthews A, Zeller MH, Lin J (2024) Practical guidelines for eating disorder risk mitigation in patients undergoing obesity treatment for the pediatric provider. Curr Opin Pediatr 36(4):367\u2013374. https:\/\/doi.org\/10.1097\/mop.0000000000001356","journal-title":"Curr Opin Pediatr"},{"issue":"4","key":"1833_CR31","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3758\/s13428-021-01694-3","volume":"54","author":"E Peer","year":"2022","unstructured":"Peer E, Rothschild D, Gordon A, Evernden Z, Damer E (2022) Data quality of platforms and panels for online behavioral research. Behav Res Methods 54(4):1643\u20131662. https:\/\/doi.org\/10.3758\/s13428-021-01694-3","journal-title":"Behav Res Methods"},{"key":"1833_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jesp.2017.01.006","volume":"70","author":"E Peer","year":"2017","unstructured":"Peer E, Brandimarte L, Samat S, Acquisti A (2017) Beyond the Turk: alternative platforms for crowdsourcing behavioral research. J Exp Soc Psychol 70:153\u2013163. https:\/\/doi.org\/10.1016\/j.jesp.2017.01.006","journal-title":"J Exp Soc Psychol"},{"key":"1833_CR33","unstructured":"Prolific Academic L (2025) https:\/\/www.prolific.com\/participant-pool. Accessed 2024"},{"key":"1833_CR34","unstructured":"Centers for Disease Control: About Adult BMI (2020) https:\/\/www.cdc.gov\/healthyweight\/assessing\/bmi\/adult_bmi\/index.html. Accessed 2025"},{"issue":"3","key":"1833_CR35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/eat.22358","volume":"48","author":"CM Grilo","year":"2015","unstructured":"Grilo CM, Reas DL, Hopwood CJ, Crosby RD (2015) Factor structure and construct validity of the Eating Disorder Examination-Questionnaire in college students: further support for a modified brief version. Int J Eat Disord 48(3):284\u2013289. https:\/\/doi.org\/10.1002\/eat.22358","journal-title":"Int J Eat Disord"},{"key":"1833_CR36","unstructured":"IBM Corp (2022) IBM SPSS Statistics (Version 29.0). Armonk, NY"},{"issue":"4","key":"1833_CR37","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang A-G (2009) Statistical power analyses using G* power 3.1: tests for correlation and regression analyses. Behav Res Methods 41(4):1149\u20131160. https:\/\/doi.org\/10.3758\/BRM.41.4.1149","journal-title":"Behav Res Methods"},{"key":"1833_CR38","unstructured":"Centers for Disease Control: Adult BMI Categories (2025) https:\/\/www.cdc.gov\/bmi\/adult-calculator\/bmi-categories.html. Accessed 2025"},{"key":"1833_CR39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24288","author":"F Celletti","year":"2025","unstructured":"Celletti F, Farrar J, De Regil L (2025) World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.24288","journal-title":"JAMA"},{"issue":"1","key":"1833_CR40","doi-asserted-by":"publisher","first-page":"e230405","DOI":"10.1530\/joe-23-0405","volume":"262","author":"KN Balantekin","year":"2024","unstructured":"Balantekin KN, Kretz MJ, Mietlicki-Baase EG (2024) The emerging role of glucagon-like peptide 1 in binge eating. J Endocrinol 262(1):e230405. https:\/\/doi.org\/10.1530\/joe-23-0405","journal-title":"J Endocrinol"},{"issue":"4","key":"1833_CR41","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41366-021-01032-9","volume":"46","author":"DJ Heal","year":"2022","unstructured":"Heal DJ, Gosden J (2022) What pharmacological interventions are effective in binge-eating disorder? Insights from a critical evaluation of the evidence from clinical trials. Int J Obes 46(4):677\u2013695. https:\/\/doi.org\/10.1038\/s41366-021-01032-9","journal-title":"Int J Obes"},{"issue":"1","key":"1833_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clinthera.2020.10.010","volume":"43","author":"CM Grilo","year":"2021","unstructured":"Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R (2021) Naltrexone\u00a0+ Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: a\u00a0Randomized, Controlled Pilot Study. Clin Ther 43(1):112\u201322.e1. https:\/\/doi.org\/10.1016\/j.clinthera.2020.10.010","journal-title":"Clin Ther"},{"issue":"11","key":"1833_CR43","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/oby.23898","volume":"31","author":"CM Grilo","year":"2023","unstructured":"Grilo CM, Lydecker JA, Jastreboff AM, Pittman B, McKee SA (2023) Naltrexone\/bupropion for binge-eating disorder: a randomized, double-blind, placebo-controlled trial. Obesity 31(11):2762\u20132773. https:\/\/doi.org\/10.1002\/oby.23898","journal-title":"Obesity"},{"key":"1833_CR44","doi-asserted-by":"publisher","first-page":"100333","DOI":"10.1016\/j.jcte.2024.100333","volume":"35","author":"L Aoun","year":"2024","unstructured":"Aoun L, Almardini S, Saliba F, Haddadin F, Mourad O, Jdaidani J et al (2024) GLP-1 receptor agonists: a novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review. J Clin Transl Endocrinol 35:100333. https:\/\/doi.org\/10.1016\/j.jcte.2024.100333","journal-title":"J Clin Transl Endocrinol"},{"issue":"8","key":"1833_CR45","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/15622975.2023.2179663","volume":"24","author":"H Himmerich","year":"2023","unstructured":"Himmerich H, Lewis YD, Conti C, Mutwalli H, Karwautz A, Sj\u00f6gren JM et al (2023) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. World J Biol Psychiatry 24(8):643\u2013706. https:\/\/doi.org\/10.1080\/15622975.2023.2179663","journal-title":"World J Biol Psychiatry"},{"key":"1833_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bodyim.2023.04.008","volume":"46","author":"EN Harrop","year":"2023","unstructured":"Harrop EN, Hutcheson R, Harner V, Mensinger JL, Lindhorst T (2023) You don\u2019t look anorexic\u201d: atypical anorexia patient experiences of weight stigma in medical care. Body Image 46:48\u201361. https:\/\/doi.org\/10.1016\/j.bodyim.2023.04.008","journal-title":"Body Image"},{"issue":"4","key":"1833_CR47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cppeds.2017.02.003","volume":"47","author":"L Moskowitz","year":"2017","unstructured":"Moskowitz L, Weiselberg E (2017) Anorexia nervosa\/atypical anorexia nervosa. Curr Probl Pediatr Adolesc Health Care 47(4):70\u201384. https:\/\/doi.org\/10.1016\/j.cppeds.2017.02.003","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"2","key":"1833_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/21604851.2024.2307674","volume":"13","author":"F Oswald","year":"2024","unstructured":"Oswald F (2024) Anti-fatness in the Ozempic era: state of the landscape and considerations for future research. Fat Stud 13(2):128\u2013134. https:\/\/doi.org\/10.1080\/21604851.2024.2307674","journal-title":"Fat Stud"},{"key":"1833_CR49","doi-asserted-by":"publisher","DOI":"10.1037\/12304-000","volume-title":"Self-objectification in women: causes, consequences, and counteractions","author":"RM Calogero","year":"2011","unstructured":"Calogero RM, Tantleff-Dunn S, Thompson JK (2011) Self-objectification in women: causes, consequences, and counteractions. American Psychological Association, Washington, DC"},{"issue":"12","key":"1833_CR50","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/oby.22581","volume":"27","author":"DR Saxon","year":"2019","unstructured":"Saxon DR, Iwamoto SJ, Mettenbrink CJ, McCormick E, Arterburn D, Daley MF et al (2019) Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009-2015. Obesity 27(12):1975\u20131981. https:\/\/doi.org\/10.1002\/oby.22581","journal-title":"Obesity"},{"issue":"11","key":"1833_CR51","doi-asserted-by":"publisher","first-page":"e1915219","DOI":"10.1001\/jamanetworkopen.2019.15219.","volume":"2","author":"L Han","year":"2019","unstructured":"Han L, You D, Zeng F, Feng X, Astell-Burt T, Duan S et al (2019) Trends in self-perceived weight status, weight loss attempts, and weight loss strategies among adults in the United States, 1999-2016. JAMA Netw Open 2(11):e1915219. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.15219.","journal-title":"JAMA Netw Open"},{"key":"1833_CR52","unstructured":"U.S. Food & Drug Administration (2024) Questions and Answers on Dietary Supplements. https:\/\/www.fda.gov\/food\/information-consumers-using-dietary-supplements\/questions-and-answers-dietary-supplements. Accessed 2025."},{"issue":"5","key":"1833_CR53","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/phh.0000000000000142","volume":"21","author":"JL Pomeranz","year":"2015","unstructured":"Pomeranz JL, Barbosa G, Killian C, Austin SB (2015) The dangerous mix of adolescents and dietary supplements for weight loss and muscle building: legal strategies for state action. J Public Health Manag Pract 21(5):496\u2013503. https:\/\/doi.org\/10.1097\/phh.0000000000000142","journal-title":"J Public Health Manag Pract"},{"issue":"6","key":"1833_CR54","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.amepre.2022.07.005","volume":"63","author":"MW Long","year":"2022","unstructured":"Long MW, Ward ZJ, Wright DR, Rodriguez P, Tefft NW, Austin SB (2022) Cost-effectiveness of 5 public health approaches to prevent eating disorders. Am J Prev Med 63(6):935\u201343. https:\/\/doi.org\/10.1016\/j.amepre.2022.07.005","journal-title":"Am J Prev Med"}],"container-title":["Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40519-026-01833-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40519-026-01833-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40519-026-01833-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:45:14Z","timestamp":1776163514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40519-026-01833-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1833"],"URL":"https:\/\/doi.org\/10.1007\/s40519-026-01833-9","relation":{},"ISSN":["1590-1262"],"issn-type":[{"value":"1590-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The Penn State University Human Research Protection Program declared this research exempt from formal IRB review based on the policies of this institution and the provisions of applicable federal regulations\n                      .\n                      Informed consent was obtained electronically from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}